Oct, 01 2019 11:46 JST

Source: Eisai

Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress


TOKYO, Oct, 01 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kinase inhibitor discovered by Eisai , plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy. The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).

For the full report, visit https://www.eisai.com/news/2019/pdf/enews201977pdf.pdf.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.


Contact:
Eisai Co., Ltd. 
Media Relations 
+81-(0)3-3817-5120

Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations 
Pamela Eisele: (267) 305-3558 
Kristen Drake: (908) 334-4688
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan
January 23 2020 14:57 JST
 
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation
January 23 2020 14:46 JST
 
Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019
January 20 2020 14:21 JST
 
Eisai's Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in China
January 06 2020 08:57 JST
 
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval
December 24 2019 16:22 JST
 
U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients
December 23 2019 08:17 JST
 
Commencement of Major Renovation of Tsukuba Research Laboratories as Eisai Global Drug Discovery Center Aiming for Connecting Human and Human, and Data, and the World
December 10 2019 08:02 JST
 
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
December 09 2019 08:36 JST
 
Eisai Satisfies All-Case Surveillance Condition for Approval of Anti-Cancer Agent Lenvima in Treatment of Thyroid Cancer
December 09 2019 08:17 JST
 
Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium
December 05 2019 08:11 JST
 
More Press release >>

Latest Press Release


More Latest Release >>